Apogee Therapeutics (APGE) Change in Accured Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Change in Accured Expenses data on file, last reported at $4.7 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 77.02% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $957000.0 (down 91.04% YoY) and the FY2025 annual result came in at -$1.1 million, down 117.07% from the prior year.
• Change in Accured Expenses climbed to $4.7 million in Q1 2026 per APGE's latest filing, from -$6.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.9 million in Q3 2023 and bottomed at -$6.4 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $1.8 million (2024), against an average of $1.6 million.
• The widest annual swing landed in 2024, when Change in Accured Expenses tumbled 769.35%; it then surged 250.94% in 2025.
• Tracing APGE's Change in Accured Expenses over 5 years: stood at $1.9 million in 2022, then tumbled by 34.28% to $1.2 million in 2023, then plunged by 414.77% to -$3.9 million in 2024, then slumped by 63.46% to -$6.4 million in 2025, then surged by 172.81% to $4.7 million in 2026.
• Per Business Quant, the three latest APGE Change in Accured Expenses figures stand at $4.7 million (Q1 2026), -$6.4 million (Q4 2025), and $7.7 million (Q3 2025).

Peer Comparison